Fintel reports that on April 5, 2023, Guggenheim upgraded their outlook for InflaRx N.V. (NASDAQ:IFRX) from Neutral to Buy .
Analyst Price Forecast Suggests 16.39% Downside
As of March 30, 2023, the average one-year price target for InflaRx N.V. is $5.10. The forecasts range from a low of $2.02 to a high of $8.40. The average price target represents a decrease of 16.39% from its latest reported closing price of $6.10.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for InflaRx N.V. is $7MM. The projected annual non-GAAP EPS is -$0.93.
What are Other Shareholders Doing?
UBS Group holds 1K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 5K shares, representing a decrease of 963.69%. The firm decreased its portfolio allocation in IFRX by 90.50% over the last quarter.
Simplex Trading holds 29K shares representing 0.06% ownership of the company. In it's prior filing, the firm reported owning 6K shares, representing an increase of 77.66%. The firm increased its portfolio allocation in IFRX by 403.79% over the last quarter.
Acadian Asset Management holds 19K shares representing 0.04% ownership of the company. In it's prior filing, the firm reported owning 9K shares, representing an increase of 51.05%. The firm increased its portfolio allocation in IFRX by 116.14% over the last quarter.
Pacifica Partners holds 21K shares representing 0.05% ownership of the company. No change in the last quarter.
Bank Of America holds 0K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 26K shares, representing a decrease of 58,164.44%. The firm decreased its portfolio allocation in IFRX by 100.00% over the last quarter.
What is the Fund Sentiment?
There are 33 funds or institutions reporting positions in InflaRx N.V..
This is a decrease
of
1
owner(s) or 2.94% in the last quarter.
Average portfolio weight of all funds dedicated to IFRX is 0.02%,
an increase
of 6.00%.
Total shares owned by institutions decreased
in the last three months by 7.42% to 3,712K shares.
The put/call ratio of IFRX is 0.06, indicating a
bullish
outlook.
InflaRx N.V. Background Information
(This description is provided by the company.)
InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA.
See all InflaRx N.V. regulatory filings.This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
